Pfizer Financial Statements

Pfizer (PFIZER) reported revenue of ₹25.20B in FY2026 with net income of ₹7.22B. Total assets stood at ₹49.22B. Net worth was ₹42.03B (₹4,203 Cr) and free cash flow was ₹9.42B.

Pfizer Income Statement

Hover the chart icon for year-over-year change.

FY 2025 – FY 2026

Item	Chart	2025	2026
Revenue		22.81B	25.20B
Cost of Rev. Cost of Revenue		-8.10B	-8.84B
Gross Profit		14.71B	16.35B
SGA Sales, General & Admin		-7.31B	-7.31B
Op. Income Operating Income		6.79B	8.46B
PBT Profit Before Tax		10.16B	9.76B
Net Income		7.68B	7.22B
Dil. Shares Diluted Shares		45.75M	45.75M
Diluted EPS		167.79	157.92

Figures in ₹ — millions (M), billions (B), trillions (T). EPS is earnings per share.

Understanding the Income Statement

The income statement shows Pfizer's revenue and expenses over a period. Revenue minus costs gives gross profit; after operating expenses, interest, and taxes, the remainder is net income. Diluted EPS divides net income by all shares that could exist if options and convertibles were exercised.

Pfizer Balance Sheet

Hover the chart icon for year-over-year change.

FY 2025 – FY 2026

Item	Chart	2025	2026
Curr. assets Total current assets		35.13B	38.03B
Non-curr. assets Total non-current assets		13.98B	11.19B
Total assets		49.11B	49.22B
Curr. liabilities Total current liabilities		5.70B	6.27B
Non-curr. liab. Total non-current liabilities		1.24B	915.00M
Total liabilities		6.94B	7.19B
Total equity		42.17B	42.03B
Total liab. & eq. Total liabilities & equity		49.11B	49.22B

Figures in ₹ — millions (M), billions (B), trillions (T).

Understanding the Balance Sheet

The balance sheet captures Pfizer's financial position at a point in time — what it owns (assets), what it owes (liabilities), and the residual value to shareholders (equity). Total assets always equals total liabilities plus equity.

Pfizer Cash Flow Statement

Hover the chart icon for year-over-year change.

FY 2025 – FY 2026

Item	Chart	2025	2026
Net Income		10.16B	9.76B
Operating CF Cash flow Operating Activities		6.60B	9.68B
Capex Investments in PPE		-281.50M	-252.30M
Investing CF Cash flow Investing Activities		-713.40M	-5.62B
Dividend Paid		-1.60B	-7.52B
Financing CF Cash flow Financing Activities		-2.05B	-7.98B
Cash (start) Cash at beginning of period		1.12B	4.95B
Cash (end) Cash at end of period		4.95B	1.03B
FCF Free Cash Flow		6.32B	9.42B

Figures in ₹ — millions (M), billions (B), trillions (T).

Understanding Cash Flow

The cash flow statement tracks how Pfizer's cash moves through operations, investing, and financing activities. Free cash flow — operating cash minus capital expenditure — shows what is available to return to shareholders.

Data from audited consolidated filings. For educational purposes only — not investment advice. Last update: Mar-2026